Gday Duke. Thanks for the article.
There have been several lately along the same lines. That is. the virus used to load the gene therapy is causing harm, as it is required to be a large amount per patient weight to carry the required dose size.
This is limiting dose size for the treatment, which in turn reduces the gene therapy efficacy.
I agree. it is positive for ANP. Perhaps the control of fibrosis (ATL1102) will allow smaller gene therapy dosr sizes to work better? Hopefully the combo study will shed some light on this.
For General Information, page-2149
-
- There are more pages in this discussion • 1,386 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |